Genzyme Nabs Elusive Lemtrada Approval, But As Third-Line MS Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says therapy for relapsing multiple sclerosis should be reserved for patients who fail two or more other MS treatments; REMS includes four-year follow up.